APAC IPOs & Placements, Aequitas Research

Nicholas Tan

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sumitomo-pharma-co" target="_blank" data-smartkarma-citation="entities:1935:1" rel="noopener">Sumitomo Pharma (4506 JP)</a> is looking to raise US$664m in a primary offering.</li>
<li>Proceeds will be used for R&amp;D in oncology, neurodegenerative and infectious diseases, and  investments in regenerative medicine/cell therapy.</li>
<li>In this note, we will talk about the placement and run the deal through our ECM framework.</li>
</ul>



Sumitomo Pharma (4506 JP) is looking to raise US$664m in a primary offering.
Proceeds will be used for R&amp;D in oncology, neurodegenerative and infectious diseases, and  investments in regenerative medicine/cell therapy.
In this note, we will talk about the placement and run the deal through our ECM framework.


Aequitas Research: Sumitomo Pharma Placement - Good Financial Performance Recently; Small in ADV